11,491 results match your criteria acute myelogenous


First Reported Case of Invasive Cutaneous Infection in a Patient With Acute Myelogenous Leukemia: A Case Report and Literature Review.

Open Forum Infect Dis 2021 Jul 23;8(7):ofab265. Epub 2021 May 23.

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Certain species are emerging opportunistic pathogens. While these can be common causes of airborne contamination of clinical cultures, an increasing number of reports describe clinically significant disease in the immunocompromised population, particularly in patients with hematologic malignancy. The typical site of infection is respiratory, but disseminated infection is also reported with some frequency. Read More

View Article and Full-Text PDF

Complex Chromosome-Positive Acute Myelogenous Leukemia Identified 16 Months following the Completion of Capecitabine Chemotherapy for Early-Stage Colon Cancer.

Case Rep Oncol 2021 May-Aug;14(2):918-921. Epub 2021 Jun 17.

Department of Internal Medicine, Chaophya Hospital, Bangkok, Thailand.

Capecitabine is an oral chemotherapy that is used to treat several cancer types, including breast, gastrointestinal, hepatobiliary, and ovarian. The use of antimetabolites in cancer therapy has generally not been associated with leukemogenesis. In this report, we demonstrate a case of capecitabine-related acute myeloid leukemia that was diagnosed 16 months after the completion of treatment for early-stage colon cancer, by a complex chromosome analysis 48,XY,6,del(7)(q22),+8,+13,t(13;17)(q12;p13),t(13,21)(q12;122),+mar [Gazi Med J. Read More

View Article and Full-Text PDF

Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.

Mol Med Rep 2021 04 5;23(4). Epub 2021 Jul 5.

Laboratory of Pathology, Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.

Acute myelogenous leukemia (AML) is frequently accompanied by a poor prognosis. The majority of patients with AML will experience recurrence due to multiple drug resistance. Our previous study reported that targeting the mTOR pathway may increase cell sensitivity to doxorubicin (Doxo) and provide an improved therapeutic approach to leukemia. Read More

View Article and Full-Text PDF

typhlitis in a patient with acute myelogenous leukemia.

Clin Case Rep 2021 Jun 24;9(6):e04290. Epub 2021 Jun 24.

Division of Hematology/Oncology Department of Internal Medicine University of Cincinnati Cincinnati OH USA.

While patients undergoing treatment for hematologic malignancies are at risk for a variety of infections, gastrointestinal mucormycosis is a rare and feared complication. Diagnosis requires a high index of suspicion and timely evaluation. Prompt treatment improves patient outcomes. Read More

View Article and Full-Text PDF

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.

Clin Case Rep 2021 Jun 23;9(6):e04287. Epub 2021 Jun 23.

Division of Pathology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.

Elevated NF-kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF-kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib. Read More

View Article and Full-Text PDF

Vancomycin-resistant COLONIZATION and infection in a HEMATOLOGIC patient.

Acta Clin Croat 2020 Sep;59(3):523-528

1Department of Clinical Microbiology, Split University Hospital Centre, Split, Croatia;2University of Split School of Medicine, Split, Croatia; 3Department of Clinical Epidemiology, Split University Hospital Centre, Split, Croatia; 4Department of Infectious Diseases, Split University Hospital Centre, Split, Croatia.

Vancomycin-resistant enterococci (VRE), especially , have emerged as significant nosocomial pathogens and patients with impaired host defenses are at a particular risk of VRE infection. The most common occurrence is asymptomatic colonization of the gastrointestinal tract that can persist for a long time and serve as a reservoir for transmission of VRE to other patients. We present a case of a patient who was diagnosed with acute myelogenous leukemia and suffered from bone marrow aplasia following induction therapy. Read More

View Article and Full-Text PDF
September 2020

Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Transplant Cell Ther 2021 Jun 23. Epub 2021 Jun 23.

Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.

Limited information is available on the efficacy of post-transplantation cyclophosphamide (PTcy) or thymoglobulin for graft-versus-host disease (GVHD) prophylaxis in mismatched unrelated donor (MMUD) transplants. We retrospectively compared outcomes of 76 adult patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) who underwent 7/8 HLA-MMUD transplantation and received either PTcy (50 mg/kg on day 3 and 4) or thymoglobulin (total dose 4.5 mg/kg) for GVHD prophylaxis. Read More

View Article and Full-Text PDF

Anti-NKG2C/IL-15/anti-CD33 Killer Engager Directs Primary and iPSC-derived NKG2C NK cells to Specifically Target Myeloid Leukemia.

Mol Ther 2021 Jun 23. Epub 2021 Jun 23.

Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN. Electronic address:

Natural killer cells mediate cytolysis of transformed cells and are currently used as an adoptive cellular therapy to treat cancer. Infection with human cytomegalovirus has been shown to expand a subset of "adaptive" NK cells, expressing the activation receptor NKG2C, that have preferred functional attributes distinct from conventional NK cells. Because NKG2C delivers a strong activating signal to NK cells, we hypothesized that NKG2C could specifically trigger NK cell-mediated antitumor responses. Read More

View Article and Full-Text PDF

A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MADESIO protocol.

PLoS One 2021 24;16(6):e0253526. Epub 2021 Jun 24.

Centre for Research in Epidemiology, Biostatistics, and Clinical Research, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium.

Background: Patients with haematologic malignancies are increasingly treated by oral anticancer medications, heightening the challenge of ensuring optimal adherence to treatment. However, except for chronic myelogenous leukaemia or acute lymphoid leukaemia, the extent of non-adherence has rarely been investigated in outpatient settings, particularly for migrant population. With growing numbers of migrants in Belgium, identifying potential differences in drug use is essential. Read More

View Article and Full-Text PDF

Apoptotic mechanisms of myricitrin isolated from Madhuca longifolia leaves in HL-60 leukemia cells.

Mol Biol Rep 2021 Jun 22. Epub 2021 Jun 22.

Medicinal Chemistry and Immunology Lab (ASK-II-406), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India.

Myricitrin, a naturally occurring flavonoid in Madhuca longifolia, possesses several medicinal properties. Even though our earlier work revealed its role against the proliferation of acute myelogenous leukemia cells (HL-60), its molecular mechanisms have not yet been revealed. The current study aims to explore the molecular mechanisms of myricitrin (isolated from an ethnomedicinal drug Madhuca longifolia) to induce apoptosis in HL-60 cells. Read More

View Article and Full-Text PDF

Core binding factor acute myelogenous leukemia-2021 treatment algorithm.

Blood Cancer J 2021 Jun 16;11(6):114. Epub 2021 Jun 16.

Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.

Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective implementation of available therapeutic measures and appropriate disease monitoring. The incorporation of gemtuzumab ozogamicin into frontline therapy should be standard. Read More

View Article and Full-Text PDF

Febrile Neutropenia Syndromes in Children: Risk Factors and Outcomes of Primary, Prolonged, and Recurrent Fever.

J Pediatr Hematol Oncol 2021 Jun 16. Epub 2021 Jun 16.

Departments of Pediatrics Medicine, Division of Infectious Diseases, University of Chicago Medicine Center for Health and the Social Sciences, University of Chicago, Chicago, IL Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA Department of Pediatrics, Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Immunocompromised Host Infectious Disease Cincinnati, OH.

Background: The approach to recurrent febrile neutropenia (FN) in children with cancer has not been sufficiently addressed and was cited as a research gap in the International Pediatric Fever and Neutropenia (IPFNP) Guideline 2017.

Methods: Retrospective medical record review for all pediatric cancer patients with a diagnosis of FN was performed. Variables were collected at 2 different time sets (at day 1 and day 4 of presentation). Read More

View Article and Full-Text PDF

Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia.

Transplant Cell Ther 2021 Jun 9. Epub 2021 Jun 9.

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:

Minimal/measurable residual disease (MRD) before allogeneic stem cell transplantation (allo-SCT) in patients with acute myelogenous leukemia (AML) is a poor risk factor for outcome. γδ T cells represent a unique minority lymphocyte population that is preferentially located in peripheral tissues, can recognize antigens in a non-MHC-restricted manner, and plays a "bridging" role between the innate and adaptive immune systems. In this study, we investigated a potential graft-versus-leukemia effect of γδ T cell reconstitution post-transplantation in AML patients with pretransplantation positive MRD status (MRD). Read More

View Article and Full-Text PDF

Following Transplantation for Acute Myelogenous Leukemia, Donor Better Protects against Relapse than .

J Immunol 2021 Jun 11. Epub 2021 Jun 11.

Department of Structural Biology, Stanford University, Stanford, CA;

In the treatment of acute myelogenous leukemia with allogeneic hematopoietic cell transplantation, we previously demonstrated that there is a greater protection from relapse of leukemia when the hematopoietic cell transplantation donor has either the / genotype or a genotype having two or more gene segments. In those earlier analyses, genotyping could only be assessed at the low resolution of gene presence or absence. To give the analysis greater depth, we developed high-resolution sequence-based typing that defines all the alleles and distinguishes the expressed alleles from those that are not expressed. Read More

View Article and Full-Text PDF

[Age does not affect the outcome of allogeneic hematopoietic precursor transplantation for acute myeloid leukemia].

Rev Med Chil 2021 Jan;149(1):22-29

Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. Read More

View Article and Full-Text PDF
January 2021

Catastrophic cerebral sinovenous thrombosis with haemorrhagic conversion in a new diagnosis of paediatric acute myelogenous leukaemia.

BMJ Case Rep 2021 Jun 7;14(6). Epub 2021 Jun 7.

Pediatric Hematology Oncology, University of Michigan Hospital, Ann Arbor, Michigan, USA.

View Article and Full-Text PDF

Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.

J Stroke Cerebrovasc Dis 2021 Aug 2;30(8):105883. Epub 2021 Jun 2.

Department of Neurology, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, United States.

Nilotinib, a BCR-ABL tyrosine kinase inhibitor (TKI), has been associated with vascular events and accelerated arterial stenosis, presumably of atherosclerotic etiology. Studies of nilotinib-associated atherosclerosis are mainly associated with progressive peripheral artery occlusive disease (PAOD), and only a few cases of coronary artery disease (CAD), and cerebrovascular disease (CVD) have been reported. The mechanisms by which nilotinib promotes atherosclerosis are poorly understood but endothelial and perivascular factors, mast cell depletion, and metabolic factors such as promotion of dyslipidemia and impaired glucose metabolism are thought to play a role. Read More

View Article and Full-Text PDF

Hospital acquired infection in a department of hematology-oncology care in the Congo.

Am J Blood Res 2021 15;11(2):191-198. Epub 2021 Apr 15.

Department of Hematology, Teaching Hospital 13 Auxence Ikonga Avenue, P.O Box 32, Brazzaville, Congo.

Objectives: Hospital Acquired Infection (HAI) is a major cause of morbidity and mortality in hemato-oncology. The study aims to report the incidence of hospital-acquired infections in patients with hematological malignancies and the risk factors associated with them.

Material And Methods: An observational study with cross-sectional data collection was carried out from January 1, 2019, to April 30, 2020, in the department of hematology of Brazzaville University Hospital. Read More

View Article and Full-Text PDF

Bis-Bibenzyls from the Liverwort and Their Biological Activity.

Plants (Basel) 2021 May 26;10(6). Epub 2021 May 26.

Institute of Botany and Botanical Garden "Jevremovac", Faculty of Biology, University of Belgrade, 11000 Begrade, Serbia.

Based on previous investigations where bis-bibenzyls isolated from liverworts showed various biological activities (cytotoxic, antimicrobial, and antiviral), we investigated their cytotoxic activity in several human cancer cell lines. From the methylene-chloride/methanol extract of the liverwort , three bis-bibenzyls of the perrottetin type were isolated, namely perrottetin E, 10'-hydroxyperrottetin E, and 10,10'-dihydroxyperrottetin E. The last two were found for the first time in this species. Read More

View Article and Full-Text PDF

Clinical Pharmacology of Antibody-Drug Conjugates.

Authors:
Iftekhar Mahmood

Antibodies (Basel) 2021 May 21;10(2). Epub 2021 May 21.

Mahmood Clinical Pharmacology Consultancy, LLC, Rockville, MD 20850, USA.

Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since the approval of first ADC (Gemtuzumab ozogamicin (trade name: Mylotarg)) for the treatment of CD33-positive acute myelogenous leukemia, several ADCs have been developed for the treatment of cancer. The goal of an ADC as a cancer agent is to release the cytotoxic drug to kill the tumor cells without harming the normal or healthy cells. Read More

View Article and Full-Text PDF

A novel all-trans retinoic acid derivative regulates cell cycle and differentiation of myelodysplastic syndrome cells by USO1.

Eur J Pharmacol 2021 Sep 29;906:174199. Epub 2021 May 29.

Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, China; The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, China. Electronic address:

4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR), a novel all-trans retinoic acid (ATRA) derivative, has been demonstrated that it had a variety of anti-tumor effects by exerting regulation on cellular proliferation, apoptosis and differentiation. Here, we found that ATPR is critical for alleviating myelodysplastic syndrome (MDS) and acute myelogenous leukemia. USO1, vesicle transport factor, belongs to tether protein family and involved in endoplasmic reticulum to Golgi trafficking of protein which is important to tumorigenesis. Read More

View Article and Full-Text PDF
September 2021

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment.

Case Rep Hematol 2021 3;2021:5518727. Epub 2021 May 3.

Department of Hematology Nephrology and Rheumatology, Akita University, 1-1 Hondo 1-Chome, Akita 010-8543, Japan.

In the era of tyrosine kinase inhibitor (TKI) treatment, its effectiveness in treating chronic myelogenous leukemia (CML) has been improved, ensuring the same prognosis as that of healthy people of the same age. However, there are some patients with de novo blast crisis that undergoes acute conversion from the time of diagnosis and does not respond to TKI treatment, especially in the older patients. Here, we present a case of an older patient with de novo lymphoid crisis who was first treated with a combination of TKI and chemotherapy, but it was difficult to maintain a durable deep molecular response (DMR). Read More

View Article and Full-Text PDF

Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.

Transplant Cell Ther 2021 May 24. Epub 2021 May 24.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

Patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) generally have poor overall survival (OS). Interventions that result in improved OS after relapse are not well established. The efficacy of second cellular therapy and specific indications are matters of debate. Read More

View Article and Full-Text PDF

Long-term immunosuppression and multiple transplants predispose systemic lupus erythematosus patients with cytopenias to hematologic malignancies.

Medicine (Baltimore) 2021 May;100(21):e25985

Department of Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY.

Abstract: Cytopenias in systemic lupus erythematosus (SLE) require clinical and laboratory workup and bone marrow (BM) examination to determine the cause and for appropriate patient management. Common causes include an increase in SLE activity, immune-mediated hemolysis, iron deficiency, antiphospholipid antibody syndrome, infection, or the effect of medications. We retrospectively evaluated the clinical and laboratory findings of patients with SLE and cytopenias who had undergone BM studies to determine the indicators of malignancy. Read More

View Article and Full-Text PDF

WeChat as a Platform for Problem-Based Learning Among Hematological Postgraduates: Feasibility and Acceptability Study.

J Med Internet Res 2021 May 25;23(5):e16463. Epub 2021 May 25.

Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Background: Hematological medicine is a practical discipline that is difficult to study. Problem-based learning (PBL) is an innovative student-centered teaching method wherein students define their own learning objectives from clinically based problems. Considering that WeChat is the most popular communication app in China, we selected it as a new platform for online PBL to reduce the limitations of traditional PBL in hematology teaching. Read More

View Article and Full-Text PDF

Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report.

BMC Med Genomics 2021 May 22;14(1):137. Epub 2021 May 22.

The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, USA.

Background: We report a patient with Essential Thrombocythemia (ET), subsequently diagnosed with concurrent myeloid and lymphoid leukemia. Generally, the molecular mechanisms underlying leukemic transformation of Philadelphia-negative myeloproliferative neoplasms (Ph-MPN) are poorly understood. Risk of transformation to acute myelogenous leukemia (AML) is low; transformation to both AML and acute lymphoblastic leukemia (ALL) is extremely low. Read More

View Article and Full-Text PDF

Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients.

Transplant Cell Ther 2021 May 12. Epub 2021 May 12.

Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria.

Although the risk for nonrelapse mortality (NRM) associated with early cytomegalovirus (CMV) reactivation (CMVR) after allogeneic hematopoietic stem cell transplantation (HSCT) is well established, debate is ongoing on whether CMVR may reduce the risk of primary disease relapse. The aim of this study was to evaluate relapse protection following early CMV reactivation after HSCT in the context of the recipient HLA-C killer cell immunoglobulin-like receptor ligands (KIRLs). In this retrospective bicentric study, 406 matched related or unrelated donor transplantations for acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) were stratified by HLA-C KIRL group (homozygous versus heterozygous) and analyzed separately for the impact of early CMVR on the cumulative incidences of relapse, NRM, and acute and chronic graft-versus-host-disease (GVHD) using landmark and multistate analyses. Read More

View Article and Full-Text PDF

Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study.

J Pediatr 2021 May 13. Epub 2021 May 13.

Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, University Lyon 1, Lyon, France; Apoptosis, Cancer and Development Laboratory, INSERM U1052, CNRS UMR5286, CRCL, Lyon, France.

Objective: To obtain a national overview of the epidemiology and management of invasive fungal infections (IFIs) in France for severely immunocompromised children who were treated for acute leukemia or had undergone allogeneic hematopoietic stem cell transplantation (a-HSCT).

Study Design: We performed a national multicenter retrospective study to collect epidemiologic data for proven and probable IFIs in children with acute leukemia under first- line or relapse treatment or who had undergone a-HSCT. We also conducted a prospective practice survey to provide a national overview of IFI management in pediatric hematology units. Read More

View Article and Full-Text PDF